Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment

Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment

Treatment of systemic lupus erythematosus (SLE) currently employs agents with relatively unselective immunosuppressive properties. However, two target-specific biological drugs have been approved: belimumab (anti-B-cell-activating factor/BAFF) and anifrolumab (anti-interferon alpha receptor-1/IFNAR1...

Full description

Bibliographic Details
Main Authors:	Kyriakos A. Kirou, Maria Dall`Era, Cynthia Aranow, Hans-Joachim Anders
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-08-01
Series:	Frontiers in Immunology
Subjects:	glucocorticoids viral infection belimumab anifrolumab systemic lupus
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.980079/full

Similar Items

An update on the management of refractory cutaneous lupus erythematosus
by: Alice Verdelli, et al.
Published: (2022-09-01)

Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials
by: Stefanie Steiger, et al.
Published: (2022-09-01)

Anifrolumab for Moderate and Severe Muco-Cutaneous Lupus Erythematosus: A Monocentric Experience and Review of the Current Literature
by: Giovanni Paolino, et al.
Published: (2023-10-01)

Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
by: Marlene Plüß, et al.
Published: (2022-11-01)

EXPERIENCE WITH BELIMUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
by: E. A. Aseeva, et al.
Published: (2015-09-01)

Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab
by: Guzman M, et al.
Published: (2020-06-01)

Belimumab in systemic lupus erythematosus
by: Ankita Srivastava
Published: (2016-01-01)

Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review
by: Zhihui Liu, et al.
Published: (2022-09-01)

Rapid Response of Refractory Systemic Lupus Erythematosus Skin Manifestations to Anifrolumab—A Case-Based Review of Clinical Trial Data Suggesting a Domain-Based Therapeutic Approach
by: Marlene Plüß, et al.
Published: (2022-06-01)

Safety of belimumab in association with denosumab in a patient affected by Lupus Erythematosus: a case report
by: Marco Scarati, et al.
Published: (2017-04-01)

New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor)
by: E. L. Nasonov, et al.
Published: (2021-10-01)

Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice
by: E. L. Nasonov, et al.
Published: (2021-09-01)

Successful treatment of severe chronic cutaneous lupus with anifrolumab: A series of 6 cases
by: Eric H. Kowalski, MD, et al.
Published: (2023-07-01)

Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date
by: Felten R, et al.
Published: (2019-05-01)

Rapid response of refractory subacute cutaneous lupus after single dose anifrolumab
by: Rebecca G. Gaffney, MD, et al.
Published: (2024-02-01)

A case of Rowell syndrome with excellent improvement following anifrolumab
by: Chelsea Shope, BA, et al.
Published: (2023-01-01)

Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients
by: O. Capdevila, et al.
Published: (2023-07-01)

RESULTS OF AN OBSERVATIONAL PROSPECTIVE STUDY OF THE EFFICACY AND SAFETY OF BELIMUMAB (BENLYSTA®) IN SYSTEMIC LUPUS ERYTHEMATOSUS IN REAL CLINICAL PRACTICE
by: E. A. Aseeva, et al.
Published: (2016-03-01)

Humoral and T-Cell Mediated Response after the Third Dose of mRNA Vaccines in Patients with Systemic Lupus Erythematosus on Belimumab
by: Luca Quartuccio, et al.
Published: (2023-01-01)

Refractory dermatomyositis responsive to anifrolumab
by: Phillip S. Ang, BA, et al.
Published: (2024-01-01)

Belimumab in childhood systemic lupus erythematosus: A review of available data
by: Feng Chen, et al.
Published: (2022-07-01)

Clinical Efficacy of Routinely Administered Belimumab on Proteinuria and Neuropsychiatric Lupus
by: Marlene Plüß, et al.
Published: (2020-05-01)

Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis
by: Han Zhang, et al.
Published: (2023-12-01)

Belimumab shows promise in neuropsychiatric lupus: Another challenge to find the offender
by: Shuilian Yu, et al.
Published: (2023-06-01)

Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: case series and literature review
by: Domenico Paolo Emanuele Margiotta, et al.
Published: (2018-03-01)

Real-World Effectiveness of Belimumab in Patients with Active Lupus
by: Yuya Sumichika, et al.
Published: (2023-12-01)

Budget Impact Analysis Of Subcutaneous Belimumab In Patients With Systemic Lupus Erythematosus In Spain
by: Cevey M, et al.
Published: (2019-12-01)

Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus
by: A. G. Tolkushin, et al.
Published: (2018-11-01)

Short‐term clinical observations of belimumab in the treatment of recently diagnosed systemic lupus erythematosus
by: Chunye Wu, et al.
Published: (2022-11-01)

DUAL THERAPY WITH BIOLOGICALS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
by: A. A. Mesnyankina, et al.
Published: (2016-07-01)

Usefulness of Belimumab in Adult Patients With Systemic Lupus Erythematosus Evaluated Using Single Indexes: A Meta-Analysis and Systematic Review
by: Chisato Yoshijima, BSPharm, et al.
Published: (2024-01-01)

Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab
by: Francesca Regola, et al.
Published: (2019-04-01)

Belimumab Decreases Autophagy and Citrullination in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus
by: Tania Colasanti, et al.
Published: (2022-01-01)

Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab
by: Sabih Ul Hassan, et al.
Published: (2020-08-01)

Type I Interferons in Systemic Lupus Erythematosus: A Journey from Bench to Bedside
by: Tao Ming Sim, et al.
Published: (2022-02-01)

The rapid inhibition of B-cell activation markers by belimumab was associated with disease control in systemic lupus erythematosus patients
by: Jing Wang, et al.
Published: (2023-02-01)

Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report
by: Francesco Fontana, et al.
Published: (2018-10-01)

An impressive case of Rowell syndrome with extensive mucosal involvement successfully treated with anifrolumab
by: Daniel R. Antohi, BA, et al.
Published: (2024-03-01)

Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus
by: Hao Cheng, et al.
Published: (2022-08-01)

Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial
by: Mieke van Schaik, et al.
Published: (2022-11-01)